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Abstract
The purpose of the paper is to examine the effects that firm factors, multinational corporations, and location have 
on explicit and tacit knowledge transfers originating in US biopharmaceutical firms during a time of transition. 
Examination of all known biopharmaceutical formal tacit and explicit knowledge transfers was done. The study 
performs logistic regression to test its hypotheses. The study identifies tacit knowledge transfers with full or partial 
equity acquisitions in firms. Explicit knowledge transfers are associated with licensing agreements or product and 
technology acquisitions. The study finds biotechnology firms and private firms are more likely to transfer tacit 
knowledge than explicit knowledge. Multinational firms are more likely to acquire tacit knowledge than explicit 
knowledge. Local transfers (compared with non-local or foreign transfers) are more likely to be tacit knowledge 
transfers. Firms within clusters are also more likely to transfer explicit knowledge than tacit knowledge. Given the 
choice between tacit and explicit knowledge transfers, firms prefer tacit knowledge transfers.
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For the past several decades, knowledge has been viewed as a
key resource related to the individual, firm, industry, and
economy’s success [1, 2]. This realization has led to the
burgeoning knowledge-based view (KBV) of the firm [3, 4].
From this perspective, proponents argue that heterogeneous
knowledge bases and capabilities are the primary drivers lead-
ing to a firm’s competitive advantage and superior perfor-
mance [5], particularly in high-technology markets [6].
KBV suggests that the firm’s reason for existence is the
creation, transfer, and application of knowledge [7, 8].
Given that no one firm can generate internally all of its needed
knowledge, firms must actively and continuously acquire and/
or transfer knowledge [9, 10]. Researchers [11, 12] suggest
that firms that are able to transfer knowledge effectively are
more productive than firms that are less capable of knowledge
transfer. An associated, more practice-oriented stream [13] in
the knowledge literature called knowledge management (KM)
also examines knowledge transfers. Carayannis [14: 219] de-
scribes KM as Ba sociotechnical system of tacit and explicit
business policies and practices.^ Within both literature
streams, it remains unclear, however, as to what the nature
and direction are of knowledge transfers [15, 16].
Building upon the KBVand the KM literatures (hereinafter
knowledge literature or KL), the present paper seeks to exam-
ine (1) the nature (i.e., forms) and (2) direction (i.e., by and to
whom and location) of knowledge transfers generated in the
US biopharmaceutical market during a time of transition.
Broadly speaking, we propose that firms of different types
and residing in different locations are involved in the transfer
of different forms of knowledge. We examine the external
contractual forms of these transfers. Moreover, we examine
this phenomenon during a time of market transition or merg-
ing of industries, which is understudied. This may be helpful
for firms and industries facing disruptive innovations, such as
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the pharmaceutical industry were facing with respect to the
biotechnology industry and its heterogeneous knowledge
base.
The knowledge literature can be divided into two natures or
forms of knowledge: explicit and tacit [17, 18]. Explicit
knowledge represents the knowing about (objective knowl-
edge), whereas tacit knowledge represents the knowing how
(subjective knowledge). Both forms of knowledge can be ex-
ternally sourced or transferred by various means [19].
Explicit knowledge can be codified and is readily transfer-
able [7]. Blueprints, copyrights, patents, and trademarks are
examples of explicit knowledge. For purposes of this study,
we identify explicit knowledge transfers with two forms of
transfers: (1) license agreements and (2) product or technolo-
gy acquisitions (hereinafter technology acquisitions). Tacit
knowledge resides in individuals and is less readily transfer-
rable [20]. Firms acquire other firms in order to gain access to
tacit knowledge [21]. We identify tacit knowledge transfers
with full or partial equity acquisitions in firms (hereinafter
equity acquisitions). Both of these forms represent inter-firm
knowledge transfers.
Most KL research has focused on the transfer of tacit
knowledge [16], especially within firms (i.e., intra-firm trans-
fers). Few studies have examined the determinants of explicit
and tacit knowledge transfers (i.e., the forms of knowledge)
between firms together [16, 22]. Understanding the forms of
knowledge transfers is important, as researchers [23, 24] have
observed that firms can enhance their competitive positions by
facilitating and managing intra- and inter-firm knowledge
transfers. We focus on one aspect of this: the transfer of
inter-firm knowledge, and within the context of biopharma-
ceutical firm knowledge transfers.
In addition to the forms of knowledge, characteristics of the
transferor and transferee play an important role [25]. This in
part may be because the transfer of explicit and tacit knowl-
edge represents differing levels of commitment and control.
Equity acquisitions are viewed as higher levels of commit-
ment and control compared with licensing and technology
acquisitions [26], with different firms, such as multinational
corporations (MNCs), desiring different levels of control.
The location of the firm also may affect the form of knowl-
edge transfer. Much of the early knowledge transfer literature
assumed that knowledge mainly transferred locally [27, 28].
This may have been particularly true of biotechnology firms
that tend to cluster in specific geographic regions [29]. The
literature on location and knowledge transfers continues to
evolve with most focusing on tacit knowledge [29].
The present study adds to the knowledge literature by ex-
amining the nature and direction of knowledge transfers.
Specifically, the study’s main research questions are the fol-
lowing: (1) are biotechnology firms and private firms more
likely to transfer tacit knowledge than explicit knowledge; (2)
are MNCsmore likely to acquire tacit knowledge than explicit
knowledge; (3) are local transfers more likely to be explicit
knowledge than tacit knowledge; and (4) are firms located
within clusters more likely to transfer explicit knowledge than
tacit knowledge. Similar to other studies on knowledge [8, 15,
30], we examine these questions within the context of the
biopharmaceutical market sector. We choose a specific time
period (e.g., 2000–2006), which represents a market in tran-
sition by way of the merging of two industries with distinct
knowledge and competencies [31]. The time period under
study represents a time when biotechnology products became
the majority of products in the clinical pipeline and with some
biotechnology firms beginning to become profitable. The
study seeks to fill the gaps in the knowledge literature about
forms of knowledge transfers and their relationships with firm
factors, MNCs, and location effects, specifically during a time
of market disruption and transition.
Theory and Hypotheses Development
The Knowledge Literature
The knowledge-based view suggests that knowledge is the
most important resource for the firm [1, 32]. Without focusing
on the epistemology of knowledge or the discussion on the
loci (e.g., individuals, groups, and organizations) of knowl-
edge (which is beyond the scope of this paper), we note that
knowledge and KBV are closely associated with several the-
ories and literature streams.
The resource-based view [33, 34] can be regarded as the
foundation of KBV [8, 18]. The resource-based view (RBV)
and KBV both see knowledge as a resource leading to perfor-
mance differences among firms [4]. RBV suggests that a
firm’s resources have the potential to provide enduring com-
petitive advantage when they are inimitable and not readily
substitutable [35]. Much focus in the KBV literature has been
on tacit knowledge because it is difficult to imitate and not
readily substitutable. Explicit knowledge on the other hand is
appropriable [1], and thus, inimitable and readily substitut-
able. Some types of explicit knowledge, however, such as
patents and copyrights are legally protected [36], whichmakes
them scarce and embeds them with value. Both KBV and
RBV note, Bthe more rare and valuable knowledge a firm
has, the better its performance^ [6: 376].
KBV differs from the RBV in that KBV sees knowledge as
the most important resource. Another distinction is that the
RBV treats knowledge as a generic resource, rather than hav-
ing special properties [37]. Compared with KBV, RBV also
does not specify the differences between resources and capa-
bilities, and whether they are internal to the firm or can be
acquired externally [38]. We investigate the dynamic nature
of knowledge transferred externally by firms.
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Market in Transition and Firm Factors
From a simplified perspective, the pharmaceutical industry is
based on long-established, vertically integrated (R&D to
sales) firms with a knowledge base in organic chemistry
(and its application) that seeks to produce Bblock-buster^
drugs [39]. Biotechnology came about in the early 1970s
and is grounded in recombinant DNA technology and molec-
ular genetics [40]. Since this time, it has expanded and diver-
sified its competencies and knowledge bases to include,
among others, gene and cell therapies, monoclonal antibodies,
combinational chemistry, genomics, and bioinformatics. For
pharmaceutical firms, biotechnology may represent a
Bdramatic case of a competence-destroying innovation^ [41:
368].
Firms facing research and development issues and threats
can resolve these issues by acquiring the necessary competen-
cies from external sources of knowledge [42]. Although, phar-
maceutical firms can choose to focus on pharmaceutical prod-
ucts alone (which some still do), they can also seek to enter
into the biotechnology industry. They can do this by internal
development, joint ventures, acquisition or licensing of tech-
nologies, or acquisition of firms [39]. By the mid-1990s, most
large pharmaceutical firms had begun to engage in biotechno-
logical R&D by one or more of the above means [40]—thus,
the merging of the two industries into the biopharmaceutical
market sector.
Much of the research on relationships between pharmaceu-
tical firms and biotechnology firms has focused on strategic
alliances of various forms, such as licensing agreements and
equity joint ventures. Lerner and Merges [43] noted that
funding from strategic alliances with pharmaceutical firms
became the largest single source of financing of biotechnology
firms through the mid-1990s. The literature on strategic alli-
ances in biotechnology has been extensive [44]. Much of this
literature focuses on alliances where the biotechnology firm
engages in research and development, leaving other aspects
(i.e., approval process, manufacturing, and marketing) to the
pharmaceutical firm.
In strategic alliances, firms seek to both access and acquire
the knowledge related to the capabilities of its partners [45]. It
has been argued that learning alliances permit organizations to
increase the speed of capability development and reduce un-
certainty by acquiring and exploiting knowledge developed
by other firms [46]. Yet, as Rothaermel and Deeds [46: 218]
note, Bthe opportunity costs of an exploration–exploitation
alliance strategy in the new product development process
can potentially outweigh its benefits.^ This is true for both
partners in an alliance.
Product acquisitions and licensing agreements also may
not transfer tacit (know how) knowledge, which is more close-
ly related to the creation of innovative drugs and therapies,
and which has historically been the means of sustained
competitive advantage for pharmaceutical firms. For example,
Mowery et al. [47] studying equity joint ventures and non-
equity licensing agreements found that equity joint ventures
were more effective for the transfer of complex capabilities
than licensing agreements, and that higher levels of knowl-
edge transfer occurred in equity joint ventures than non-equity
(such as licensing) arrangements. We do not study joint ven-
tures (i.e., two entities forming a third new entity), but believe
an extension of this can be made for the comparison of non-
equity acquisitions or transfers to equity acquisitions of firms.
The biopharmaceutical market also has been the subject of
the mergers and acquisition (M&A) literature. Our study ex-
amines acquisitions, but not mergers (i.e., two entities becom-
ing a new entity). Related to our study, this stream of research
examines opportunities for firms to reconfigure their busi-
nesses and alter their pool of capabilities and resources [48].
For example, Lodh and Battaggion [49] studying biotechnol-
ogy M&As show that acquisitions of unrelated firms develop
the breadth of knowledge compared with acquisitions of re-
lated firms that mainly increase the depth of knowledge.
Additionally, the biopharmaceutical market sector is a
process-enabling sector, where process and product knowl-
edge must be well coordinated [50]. Within biotechnology,
as firms attempt to create new drugs, new processes must be
developed. As Feldman and Ronzio [51: 2] note, Bbio-
manufacturing is in itself a knowledge-generating activity.^
Furthermore, the Food and Drug Administration (FDA) re-
quires that material used in the market authorization process
be the same process that is used for the final product [52]. This
is to say that there are market authorization (FDA) reasons as
well as knowledge reasons for owning and controlling both
the drug discovery and development process.
Ultimately, given the growth in biotechnology [53] and its
perceived disruptive potential, many pharmaceutical firms
sought to further commit resources into the biotechnology
industry. During the period of our study, the pharmaceutical
industry was perceived as facing a productivity crisis with
fewer approved drugs entering the market [54]. Although
there were few biotechnology products on the market at the
end of the 1990s [55], by 2004, 60 % of the drugs in the
clinical pipeline were biotechnology products [53].
Because of the above, the extreme duration of the market
authorization process [46] and costs (which DiMasi and
Grabowski [55] estimate to be similar for pharmaceutical
and biological products during this time), pharmaceutical
firms continued to acquire both explicit and tacit knowledge.
In addition, beginning in the mid-1990s, the acquisition price
of biotechnology knowledge had decreased and may have
been lower than internal development costs [39]. This may
be because the biotechnology industry as a whole remained
unprofitable until 2008 [56]. Additionally, other external
sources of financing (e.g., venture capital and initial public
offerings) were slowing down after 2000 [57], leaving
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financing from pharmaceutical firms as a major source.
Because of these factors, we note this as a period of transition
for these two industries.
Lerner and Merges [43] examining the control rights in
strategic alliances between R&D firms (biotechnology) and
financial firms (pharmaceutical) found that the most profound
effect on the allocation of control rights is the financial con-
dition of the R&D (biotechnology) firm. In addition, their
research suggested that pharmaceutical firms in some cases
protracted negotiations weakening the financial (and thus
bargaining) position of biotechnology firms. Lerner and
Merges [43] also note that when external financial resources
were lower for the biotechnology firm, then the financing firm
had the greater leverage or bargaining power.
We extrapolate from Lerner and Merges’ [43] research and
suggest that a financing pharmaceutical firmwould likely seek
an equity position in the firm (compared with a product acqui-
sition or licensing agreement) as it may give greater access
and control of present and future technologies and knowledge.
As Kogut and Zander [58: 391] observe Bcreating new knowl-
edge does not occur in abstraction from current abilities,^ and
the Blanguage of chemical pharmaceuticals may be inadequate
for the development and transfer of biotechnologies.^ Given
the perceived disruptive threat of biotechnology, the financial
condition of the industry, and the lack of internal knowledge
of pharmaceutical firms in this area during this time, the fol-
lowing hypotheses are offered:
& H1a: Biotechnology firms (compared with pharmaceutical
firms) are more likely to transfer tacit knowledge than
explicit knowledge.
& H1b: Private firms (compared with public firms) are more
likely to transfer tacit knowledge than explicit knowledge.
Multinational Corporations
It has been suggested [59] that multinational corporations are
the major global producers and disseminators of technology.
Reus, Lamont, and Ellis [60: 933] also suggest that
Bmultinationals are a superior organizational form for trans-
ferring knowledge.^ This may be because as previous re-
search has argued transferring knowledge within firms is less
complicated than transferring knowledge across firms [9].
Furthermore, Gupta and Govindarajan [32: 473] suggest Bthe
primary reason MNCs exist is because of their ability to trans-
fer and exploit knowledge more effectively and efficiently in
the intra-corporate context than through external market
mechanisms.^ The transfer of knowledge is critical in global
businesses as MNCs serve to adopt intra-organizationally the
transfer of knowledge across borders [16].
As noted above, during the time under study, the pharma-
ceutical industry and biotechnology industry are merging.
Initially, all pharmaceutical firms, whether foreign or domes-
tic, face the same lack of knowledge challenges, with R&D
being one of the least internationalized of all activities for
firms [2]. Thus, MNCs engage in both inter-firm tacit and
explicit knowledge transfers [10], as there remains increasing
pressure on MNCs to gain knowledge from their business
environments [61].
Kogut and Zander [3: 639] note, Bfirms grow on their abil-
ity to create new knowledge and to replicate this knowledge so
as to expand their market.^ MNCs can expand into new mar-
kets by several different vehicles: licensing, exporting (such as
a technology), joint ventures, or wholly owned subsidiaries
[62, 63]. This typically is viewed from the perspective of the
firm already possessing the knowledge, but can be applied to
the firm acquiring the knowledge as well. This is to say that
MNCs can access and acquire knowledge by these vehicles.
MNCs typically operate as a network of geographically
scattered subsidiary units [64]. Kale and Singh [65] suggest
that when most large firms acquire smaller firms or when
firms in less developed countries acquire firms in more devel-
oped countries that they do not integrate the acquired firm into
a single corporation, but rather maintain their identity and
capabilities separately. Thus, an MNC may wish to acquire
the biotechnology firm as this reduces the threat of knowledge
dissemination to other firms compared with a license agree-
ment [62]. This is because transfers between subsidiaries rep-
resent the transfer of tacit knowledge, which protects against
unwanted imitation [63].
Berry [2: 871] also notes that firms are less receptive to
knowledge coming from outside the firm, with firms being
reluctant to embrace technology transfers due to the Bnot
invented here syndrome.^ Thus, strong relational ties may
be necessary for tacit knowledge transfers, in particular [2].
The acquisition of a firm and incorporation of tacit knowledge
may help reduce this Bforeignness^ issue for MNCs and
strengthen intra-firm knowledge transfers.
Similar to our arguments above, it may be that the reduced
prices for equity acquisitions in this market combined with the
greater need for control and access to knowledge will lead
MNCs to pursue tacit knowledge (equity) acquisitions com-
pared to acquisitions of explicit knowledge. Shan and Song
[66] found that foreign MNCs in the biotechnology industry
make equity investments in US biotechnology firms sourcing
country-specific, firm-embodied knowledge advantages [67].
We believe this to be true for US MNCs and pharmaceutical
MNCs. Thus, the hypothesis is
H2: Multinationals (compared with non-MNCs) are more
likely to acquire tacit knowledge than explicit knowledge.
Location and Clusters
The effect of the firm’s location in the knowledge literature as
applied to the biopharmaceutical market has been studied
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extensively [15, 68]. Geographical distance has been argued
as both a hindrance and benefit to the firm’s innovative capa-
bilities [69]. As Phene et al. note [69: 374] note, Bthe very
distance of the knowledge that makes it valuable creates dif-
ficulties in its acquisition and absorption.^
Much of the knowledge literature has examined the loca-
tion of biopharmaceutical and other firms from a social net-
work perspective. Researchers have suggested that access to
new sources of knowledge is one of the most important direct
benefits of social networks [12]. Many of the social networks
in biotechnology are formed during the researcher’s formal
education, with many firms being the product of university
spin-offs [70]. For example, Herbert Boyer of Genetech, the
first biotechnology firm, was associated with the University of
California at San Francisco. Several of Genetech’s first em-
ployees were Boyer’s former students [71].
The creation of the biotechnology industry as an offshoot
of the university setting is different than that of the pharma-
ceutical industry [31]. Historically, pharmaceutical firms have
resided mainly in the eastern portion of the USA whereas
biotechnology has been bi-coastal in the USA if not more
geographically dispersed. It also has been noted that biotech-
nology firms tend to cluster in areas where intellectual capital
(i.e., universities) and financial capital (i.e., venture capital)
co-exist [72]. Arikan [73: 658] observes that the Bknowledge-
based theory places primary emphasis on inferfirm knowledge
exchanges among cluster firms in explaining enhanced
knowledge creation within clusters.^
Studies on clusters usually concern the transfer of tacit
knowledge [12]. The clustering of embryonic firms near uni-
versities is partly explained by the need to transfer tacit knowl-
edge between university-based scientists and biotechnology
firms [74]. Biotechnology firms also engage in the transfer
of tacit knowledge between firms. This clustering is not lim-
ited to start-ups, but multinational corporations also are pres-
ent in clusters due to the tacitness of local technological
knowledge [15].
From a social network perspective, much of this knowl-
edge sharing is performed on an informal basis [72]. This
knowledge sharing may at times lead to knowledge or tech-
nology spillovers, which occur involuntarily [62] and for
which the transferor receives no monetary compensation
[73]. As Chiaroni and Chiesa [29: 1065] note Bfirms working
in the same field naturally benefit from information exchanges
concerning markets, technologies, and business partners, etc.^
Given this, the potential for knowledge spillovers may lessen
the need for tacit knowledge in the form of equity acquisition
of the firm. Thus, the hypothesis is
H3a: Local knowledge transfers (compared with non-local
transfers) are more likely to be explicit knowledge than tacit
knowledge.
Additionally, Breschi and Lissoni [74: 27] studying patent
citations in the biopharmaceutical market find that Bmobile
inventors and short social chains of co-inventors are largely
responsible for the localization of knowledge flows,^ imply-
ing that researchers are not likely to relocate outside of these
clusters, but they do change employers and take tacit knowl-
edge with them. We extrapolate from the above and suggest
that firms within clusters may be able to hire talent (i.e., access
to tacit knowledge) at a rate sufficient to lessen the need for
equity (tacit knowledge) acquisition. Thus, the hypothesis is
H3b: Firms within clusters (compared with non-cluster
firms) are more likely to transfer explicit knowledge than tacit
knowledge.
Methods
In order to examine knowledge, we use a database compiled
by Irving Levin Associates, Inc. The database includes all
known biopharmaceutical formal tacit and explicit knowledge
transfers originating from private and publicly traded firms in
the USA from 2000 through 2006. There are 555 transfers of
knowledge during our period of study. We perform binary
logistic analysis to test our hypotheses. We define explicit
knowledge transfers as license agreements or technology ac-
quisitions. We define tacit knowledge transfers as full or par-
tial equity interests in a firm.
The database gives us qualitative information. The follow-
ing describes how we re-code this information into an appro-
priate quantitative format for purposes of the study. For our
dependent variable in the binary logistic regression analysis,
we use a binary variable noting if the knowledge being trans-
ferred is by way of a license agreement or product/technology
acquisition (0) or partial or full acquisition of equity in the
transferring firm (1). An example of a license agreement
would be Ascent Pediatrics’ licensing of OPRAMED, a liquid
corticosteroid for treating pediatric asthma to BioMarin. An
example of a product/technology acquisition is Chiron
Corporation selling its San Diego-based gene therapy
manufacturing facility to Cell Genesys. An example of a par-
tial acquisition of equity would be GlaxoSmithKline acquisi-
tion of an additional 16% of Theravance. An example of a full
acquisition of equity would be Amgen’s acquisition of
Abgenix. We control for the date that the transfer occurs by
way of a continuous variable (i.e., 2000 = 1; 2001 = 2).
For our firm factor independent variables, we code a firm
(0) if the transferring (i.e., selling) firm is a biotechnology
firm, or (1) if the transferring firm is a pharmaceutical firm.
We code if the transferring (i.e., selling) firm is a private firm
(0) or a publicly traded firm (1). To determine if the firm
acquiring knowledge is a multinational firm, we use Gray’s
[75] list of top 20 biopharmaceutical firms, which is based
upon 2004 revenues. Eleven of the top 20 firms have corpo-
rate headquarters outside of the USA. We code an acquiring
firm (1) if it is a top 20-biopharmaceutical firm or (0) if not.
449J Pharm Innov (2020) 15:445–454
For the variable related to local transfer or non-local transfer,
we use Mapquest (www. Mapquest.com) to plot the distance
between the two firms. In general, we consider a distance
between the firms of 50 miles or less to be Blocal.^ A local
knowledge transfer is coded (1) and a non-local knowledge
transfer is labeled (0). For bio-clusters, we use Powell et al.’s
[74] nine bio-pharmaceutical regions. We code the variable of
the transferring firm headquartered in a geographic bio-cluster
(1) or (0) if not. Within our binary logistic regression analysis,
we use different reference categories. The following catego-
ries use the first reference variable as the comparison group:
multinational, local, and cluster. The following categories use
the last reference variable as the comparison group:
biotechnology/pharmaceutical and private/public.
Results
Table 1 shows the means and correlations associated with the
binary logistic regression analysis related to knowledge trans-
fers being either explicit (e.g., license or technology acquisi-
tion) or tacit (e.g., equity position in the firm). For our sample
of 555 knowledge transfers, there were 217 (39.1%) explicit
transfers and 338 (60.9%) tacit transfers. Chart 1 shows ex-
plicit and tacit transfers by year.
There were 275 transfers originating with biotechnology
firms (49.5%) and 280 transfers originating with pharmaceu-
tical firms (50.5%). There were 273 (49.2%) private firms
transferring knowledge compared with 282 (50.8%) public
firms. Chart 2 illustrates biotechnology/pharmaceutical firms
and private/public firms’ transfers by year.
There were 66 (11.9%) explicit or tacit knowledge acqui-
sitions by multinational firms compared with 489 (88.1%)
non-multinational firms. There were 71 (12.8%) transfers that
were local compared with 484 (87.2%) that were non-local
transfers. Three hundred sixty (64.9%) transfers originated
in a cluster, compared with 195 (35.1%) of the transfers orig-
inating in a non-cluster.
Table 2 presents the results of our binary logistic regression
analysis between firms transferring either explicit or tacit
knowledge. The results indicate a good fit of the model to
the data (Model χ2 = 154.418 (p = 0.000) and Nagelkerke
R2 = 0.329) and correctly classify 74.4% of the cases. Our
results show that all of the variables in the model are statisti-
cally significant.
Biotechnology firms were 3.475 times more likely to trans-
fer tacit knowledge than pharmaceutical firms. Private firms
were 5.800 times more likely to transfer tacit knowledge than
publicly traded firms. These two findings support our two
hypotheses related to firm factors (i.e., H1a: biotechnology
firms (compared with pharmaceutical firms) are more likely
to transfer tacit knowledge than explicit knowledge; and H1b:
private firms (compared with public firms) are more likely to
transfer tacit knowledge than explicit knowledge).
MNCswere 1.838 times more likely to acquire tacit knowl-
edge than non-multinational firms. This supports our hypoth-
esis (H2) that multinationals (compared with non-MNCs) are
more likely to acquire tacit knowledge than explicit
knowledge.
Local transfers were 2.078 times more likely to be tacit
knowledge transfers than non-local transfers. This does not
support our hypothesis (H3a) that local knowledge transfers
(compared with non-local transfers) are more likely to be
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Chart 1 Explicit and tacit knowledge transfers by year
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explicit knowledge than tacit knowledge. However, firms
within clusters were 0.522 times less likely to transfer tacit
knowledge than non-local firms. In other words, firms within
clusters were 1.916 times more likely to transfer explicit
knowledge. This supports our hypothesis (H3b) that firms
within clusters (compared with non-cluster firms) are more
likely to transfer explicit knowledge than tacit knowledge.
Discussion
The purpose of the paper is to examine the effects that firm
factors, multinational corporations, and location have on ex-
plicit and tacit knowledge transfers originating in US biophar-
maceutical firms during a time of transition. The study con-
firms four of the five hypotheses. The study finds biotechnol-
ogy firms and private firms are more likely to transfer tacit
knowledge than explicit knowledge. Multinational firms are
more likely to acquire tacit knowledge than explicit knowl-
edge. Local transfers are more likely to be tacit knowledge
transfers. Firms within clusters are also more likely to transfer
explicit knowledge than tacit knowledge.
Few studies have examined the determinants of the forms
of knowledge transfers between firms together [16].
Understanding the forms of knowledge transfers is important,
as researchers have observed that firms can enhance their
competitive positions by facilitating and managing inter-firm
knowledge transfers. The study extends the work on knowl-
edge transfers, specifically as it relates to a market in transition
that is dealing with disruptive innovation in the form of het-
erogeneous knowledge. Its findings may be generalizable (but
of need of further study) to other industries dealing with dis-
ruptive innovations, specifically during the inflection point or
time of transition (i.e., when one technology becomes preva-
lent over another such as was the case in our study [53]).
The study’s finding implies that the market sector is not
entrenched with the established knowledge related to pharma-
ceutical products, but rather is embracing new knowledge in
the form of biotechnology. These findings may show that
firms are attempting to expand their dynamic capabilities
[76] to address changes in their external environments. In this
regard, the present study adds to our knowledge about how
firms deal with disruptive innovation by the expansion of their
knowledge base via tacit knowledge transfer, specifically the
preference to acquire equity positions in biotechnology firms.
Perhaps, one significant interpretation of the results is that
given the choice between explicit and tacit knowledge, firms
are choosing tacit knowledge to be transferred or acquired.
This may be due to the importance (i.e., value) that firms in
Chart 2 Biotech/pharmaceutical
and private/public transfers
Table 2 Binary logistic regression testing explicit vs. tacit knowledge
transfers
B S.E. Sig. Exp (B)
Date − 0.175 0.058 0.003 0.840
Biotech/pharmaceutical 1.246 0.209 0.000 3.475
Private/public 1.758 0.213 0.000 5.800
MNC 0.609 0.304 0.045 1.838
Local 0.731 0.343 0.033 2.078
Cluster − 0.650 0.220 0.003 0.522
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this market sector place on R&D, as historically firms engaged
in R&D in this market sector were associated with the highest
economic rents [31]. Thus, firms may not wish to be merely
providers of downstream services (i.e., marketing and sales) as
these may be more easily replicated and replaced than creators
of innovative products.
It may also highlight a unique aspect of the biopharmaceu-
tical market related to generic drugs. Generic drugs represent a
substitute for innovative pharmaceutical products and were
increasing their market share of all pharmaceutical products
during this time [77]—thus, increasing competition within
industry. As noted above, biotechnology at this time is more
difficult to replicate. Hence, the acquisition of this biotechnol-
ogy knowledge may create additional strategic space for the
established firm, enhancing its reasons to enter this industry.
The study is not without limitations. We study
biopharmaceuticals and do not know if our results apply to
other markets. We do not include mergers or joint ventures in
our analyses, as it is too difficult to differentiate between the
firm that is transferring and the firm that is receiving knowl-
edge. Nor do we know what (previous) arrangement the firms
have or had (i.e., are/were they party to joint ventures). It
would have been helpful to include total assets and other fi-
nancial and market measures; unfortunately, we did not have
access to the financial records of private firms. We did not
examine the performance (e.g., entry of marketable drugs,
financial) between firms engaged in either explicit or tacit
knowledge transfer. We study a limited time period (2000–
2006) and do not know if our results would be the same for
other time periods, before or after.
The present study should add to our knowledge about the
forms and direction of knowledge transfers in a time of market
transition. These practices may continue as knowledge and
capabilities for one biopharmaceutical therapeutic class do
not necessarily transfer to others [31, 72]. The present study
should be of interest to scholars of knowledge, multinationals,
and location, as well as those within the biopharmaceutical
community. It should also be of interest to those studying
disruptive innovations and how firms deal with the transition
to new innovations and industries.
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